Invesaro

Stocks Health care PYPD

NASDAQ · Health care

PolyPid Ltd. (PYPD)

It posted a net loss of $34.2M. In fiscal 2025 capital spending exceeded operating cash flow by $28.1M. At December 31, 2025 it held $6.4M in cash against $988K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on February 25, 2026.

Free, no password. An email when PYPD files with the SEC.

Price
$6.24
+1.63% on the day · November 9, 2026
52-week range $3.50 to $6.48
Market cap
$126.7M

Key facts about PolyPid Ltd.

Net worth
PolyPid Ltd. has a market value (market cap) of $126.7M at the latest share price, and shareholders' equity of $11M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Cash flow
In fiscal 2025 operations used $27.9M of cash.
Latest report
The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on February 25, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR

What PolyPid Ltd. does

PolyPid Ltd. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PYPD.

Revenue and profit by year

Net income
FY18: $5.9M $5.9M FY18FY20: -$6.9M -$6.9M FY20FY20: -$36.9M -$36.9M FY20FY21: -$42.6M -$42.6M FY21FY22: -$39.6M -$39.6M FY22FY23: -$23.9M -$23.9M FY23FY24: -$29M -$29M FY24FY25: -$34.2M -$34.2M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/a-$33M-$34.2M$2.09-$28.1M
2024n/a-$28M-$29M$4.91-$22M
2023n/a-$22.9M-$23.9M$16.93-$17.4M
2022n/a-$38.9M-$39.6M$61.09-$36.1M
2021n/a-$43.1M-$42.6M$68.27-$35M
2020n/a-$26.3M-$36.9M$134.14-$22.4M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What PolyPid Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. October 1, 2026
  2. October 1, 2026
  3. August 13, 2026
  4. August 12, 2026
  5. August 12, 2026
  6. August 12, 2026
  7. August 12, 2026
  8. July 29, 2026
  9. July 21, 2026
  10. July 15, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 17, 2026. Insider transactions on SEC

Insider trades

What the people running PolyPid Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PYPD

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Aurum Ventures M.K.I. Ltd.13G, passive 24.4% 5,001,561 May 4, 2026
Rodney Hodges13G, passive with 4 related filers 13.4% 2,722,707 August 13, 2026
Yehuda Nir13G, passive 10.1% 1,071,258 May 15, 2025
Rosalind Advisors, Inc.13G, passive with 3 related filers 9.9% 5,124,011 August 12, 2026
Orin Hirschman13G, passive with 1 related filers 9.8% 1,793,117 January 30, 2026
Aharon Lukach13G, passive 5.2% 538,610 May 28, 2025

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 33 managers reported a position.

HolderSharesValueChange on quarter
AIGH Capital Management LLC1,504,741$7.6M-88,846
Rosalind Advisors, Inc.389,455$2M-208,471
DAFNA Capital Management LLC207,900$1.1M0
Morgan Stanley123,136$625.5K-53,756
Renaissance Technologies LLC116,619$592.4K+98,023
Marshall Wace, Llp115,014$584.3Knew
ADAR1 Capital Management, LLC103,950$528.1K0
Symmetry Peak Management LLC100,881$512.5K+13,688
J. Goldman & Co LP99,183$503.9K-50,316
Jane Street Group, LLC83,126$422.3K+61,484
Quadrature Capital Ltd70,939$360.4Knew
Connective Capital Management, LLC67,600$343.4Knew
Citadel Advisors LLC42,282$214.8K-15,487
Susquehanna International Group, Llp40,027$203.3Knew
Lumbard & Kellner, LLC38,200$194.1K0
XTX Topco Ltd35,047$178K+5,584
UBS Group AG18,484$93.9Knew
Axq Capital, LP17,097$86.9Knew
B. Riley Wealth Advisors, Inc.15,130$75.2K0
HighTower Advisors, LLC11,000$55.9Knew

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PYPD

What does PolyPid Ltd. do?

PolyPid Ltd. is a company in the Health care sector, listed on NASDAQ as PYPD. Its shares trade on NASDAQ under the ticker PYPD.

What is PolyPid Ltd.'s net worth?

PolyPid Ltd. has a market value (market cap) of $126.7M at the latest share price, and shareholders' equity of $11M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is PolyPid Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $34.2M.

When did PolyPid Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on February 25, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from October 1, 2026.

Similar companies

Compare PYPD with

Compare PYPD with any company

Follow PYPD

Get an email when PolyPid Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Free, no password. An email when PYPD files with the SEC.

Where the numbers come from

Financial figures are the values PolyPid Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.